Axogen Inc. Files 8-K: Regulation FD & Exhibits
Ticker: AXGN · Form: 8-K · Filed: Sep 6, 2024 · CIK: 805928
| Field | Detail |
|---|---|
| Company | Axogen, Inc. (AXGN) |
| Form Type | 8-K |
| Filed Date | Sep 6, 2024 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.01 |
| Sentiment | neutral |
Sentiment: neutral
Topics: disclosure, regulatory
Related Tickers: AXGN
TL;DR
AXGN filed a standard 8-K, no major news.
AI Summary
Axogen, Inc. filed an 8-K on September 6, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or new material events beyond the standard reporting requirements for this form type.
Why It Matters
This 8-K filing serves as a standard disclosure for Axogen, Inc., informing the public about regulatory compliance and the submission of financial exhibits.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report and does not disclose any new material events, financial results, or significant changes.
Key Players & Entities
- Axogen, Inc. (company) — Registrant
- September 6, 2024 (date) — Date of Report
- Minnesota (location) — State of Incorporation
- Alachua, Florida (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Axogen, Inc.?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and to provide Financial Statements and Exhibits.
On what date was this 8-K report filed?
This 8-K report was filed on September 6, 2024.
What is Axogen, Inc.'s state of incorporation?
Axogen, Inc. is incorporated in Minnesota.
Where are Axogen, Inc.'s principal executive offices located?
Axogen, Inc.'s principal executive offices are located in Alachua, Florida.
Does this filing indicate any new material events or financial results for Axogen, Inc.?
No, this filing is a standard 8-K report and does not indicate any new material events or specific financial results beyond the reporting of exhibits and regulatory disclosures.
Filing Stats: 518 words · 2 min read · ~2 pages · Grade level 10.3 · Accepted 2024-09-06 07:09:28
Key Financial Figures
- $0.01 — ange on which registered Common Stock, $0.01 par value AXGN The Nasdaq Stock Market
Filing Documents
- axgn-20240906.htm (8-K) — 25KB
- axgn-blasubmissioncomple.htm (EX-99.1) — 9KB
- axgn-blasubmissioncomple001.jpg (GRAPHIC) — 300KB
- axgn-blasubmissioncomple002.jpg (GRAPHIC) — 292KB
- axgn-blasubmissioncomple003.jpg (GRAPHIC) — 42KB
- 0000805928-24-000127.txt ( ) — 1032KB
- axgn-20240906.xsd (EX-101.SCH) — 2KB
- axgn-20240906_lab.xml (EX-101.LAB) — 21KB
- axgn-20240906_pre.xml (EX-101.PRE) — 12KB
- axgn-20240906_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure On September 6, 2024, Axogen Inc., (the "Company") issued a press release announcing it has completed the rolling submission process for its Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its Avance Nerve Graft. A copy of this press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. The information in this Item 7.01 is being furnished and shall not be deemed to be "filed" for purposes of Section 18 of the Exchange Act or otherwise subject to the liabilities of that section and shall not be deemed incorporated by reference into any filing under the Securities Act or Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits (d) Exhibits Exhibit No. Description 99.1 Axogen Inc. Press Release, dated September 6, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Exchange Act, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. AXOGEN, INC. Dated: September 6, 2024 By: /s/ Marc Began Marc Began Executive Vice President, General Counsel and Chief Compliance Officer